Literature DB >> 28319045

AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis.

Ni Li, Wei Xue, Huairui Yuan, Baijun Dong, Yufeng Ding, Yongfeng Liu, Min Jiang, Shan Kan, Tongyu Sun, Jiale Ren, Qiang Pan, Xiang Li, Peiyuan Zhang, Guohong Hu, Yan Wang, Xiaoming Wang, Qintong Li, Jun Qin.   

Abstract

Loss of phosphatase and tensin homolog (PTEN) and activation of the PI3K/AKT signaling pathway are hallmarks of prostate cancer (PCa). However, these alterations alone are insufficient for cells to acquire metastatic traits. Here, we have shown that the histone dimethyl transferase WHSC1 critically drives indolent PTEN-null tumors to become metastatic PCa. In a PTEN-null murine PCa model, WHSC1 overexpression in prostate epithelium cooperated with Pten deletion to produce a metastasis-prone tumor. Conversely, genetic ablation of Whsc1 prevented tumor progression in PTEN-null mice. Molecular characterization revealed that increased AKT activity due to PTEN loss directly phosphorylates WHSC1 at S172, preventing WHSC1 degradation by CRL4Cdt2 E3 ligase. Increased WHSC1 expression transcriptionally upregulates expression of RICTOR, a pivotal component of mTOR complex 2 (mTORC2), to further enhance AKT activity. Therefore, the AKT/WHSC1/mTORC2 signaling cascade represents a vicious feedback loop that elicits unrestrained AKT signaling. Furthermore, we determined that WHSC1 positively regulates Rac1 transcription to increase tumor cell motility. The biological importance of a WHSC1-mediated signaling cascade is substantiated by patient sample analysis in which WHSC1 signaling is tightly correlated with disease progression and recurrence. Taken together, our findings highlight a pivotal link between an epigenetic regulator, WHSC1, and key intracellular signaling molecules, AKT, RICTOR, and Rac1, to drive PCa metastasis.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28319045      PMCID: PMC5373871          DOI: 10.1172/JCI91144

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  55 in total

1.  Histone methyltransferase NSD2/MMSET mediates constitutive NF-κB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop.

Authors:  Ping Yang; Linlang Guo; Zhijian J Duan; Clifford G Tepper; Ling Xue; Xinbin Chen; Hsing-Jien Kung; Allen C Gao; June X Zou; Hong-Wu Chen
Journal:  Mol Cell Biol       Date:  2012-05-29       Impact factor: 4.272

2.  The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice.

Authors:  Mei-Ling Chen; Pei-Zhang Xu; Xiao-ding Peng; William S Chen; Grace Guzman; Ximing Yang; Antonio Di Cristofano; Pier Paolo Pandolfi; Nissim Hay
Journal:  Genes Dev       Date:  2006-06-15       Impact factor: 11.361

Review 3.  Molecular genetics of prostate cancer: new prospects for old challenges.

Authors:  Michael M Shen; Cory Abate-Shen
Journal:  Genes Dev       Date:  2010-09-15       Impact factor: 11.361

4.  NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming.

Authors:  Alex J Kuo; Peggie Cheung; Kaifu Chen; Barry M Zee; Mitomu Kioi; Josh Lauring; Yuanxin Xi; Ben Ho Park; Xiaobing Shi; Benjamin A Garcia; Wei Li; Or Gozani
Journal:  Mol Cell       Date:  2011-11-18       Impact factor: 17.970

5.  Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.

Authors:  Brett S Carver; Jennifer Tran; Anuradha Gopalan; Zhenbang Chen; Safa Shaikh; Arkaitz Carracedo; Andrea Alimonti; Caterina Nardella; Shohreh Varmeh; Peter T Scardino; Carlos Cordon-Cardo; William Gerald; Pier Paolo Pandolfi
Journal:  Nat Genet       Date:  2009-04-26       Impact factor: 38.330

6.  The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts.

Authors:  M Chesi; E Nardini; R S Lim; K D Smith; W M Kuehl; P L Bergsagel
Journal:  Blood       Date:  1998-11-01       Impact factor: 22.113

7.  A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf-Hirschhorn syndrome.

Authors:  Keisuke Nimura; Kiyoe Ura; Hidetaka Shiratori; Masato Ikawa; Masaru Okabe; Robert J Schwartz; Yasufumi Kaneda
Journal:  Nature       Date:  2009-05-31       Impact factor: 49.962

8.  Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer.

Authors:  Shunyou Wang; Jing Gao; Qunying Lei; Nora Rozengurt; Colin Pritchard; Jing Jiao; George V Thomas; Gang Li; Pradip Roy-Burman; Peter S Nelson; Xin Liu; Hong Wu
Journal:  Cancer Cell       Date:  2003-09       Impact factor: 31.743

9.  Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer.

Authors:  Irfan A Asangani; Bushra Ateeq; Qi Cao; Lois Dodson; Mithil Pandhi; Lakshmi P Kunju; Rohit Mehra; Robert J Lonigro; Javed Siddiqui; Nallasivam Palanisamy; Yi-Mi Wu; Xuhong Cao; Jung H Kim; Meng Zhao; Zhaohui S Qin; Mathew K Iyer; Christopher A Maher; Chandan Kumar-Sinha; Sooryanarayana Varambally; Arul M Chinnaiyan
Journal:  Mol Cell       Date:  2012-11-15       Impact factor: 17.970

10.  The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer.

Authors:  T Ezponda; R Popovic; M Y Shah; E Martinez-Garcia; Y Zheng; D-J Min; C Will; A Neri; N L Kelleher; J Yu; J D Licht
Journal:  Oncogene       Date:  2012-07-16       Impact factor: 9.867

View more
  44 in total

Review 1.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

2.  Histone methyltransferase SETD2 modulates alternative splicing to inhibit intestinal tumorigenesis.

Authors:  Huairui Yuan; Ni Li; Da Fu; Jiale Ren; Jingyi Hui; Junjie Peng; Yongfeng Liu; Tong Qiu; Min Jiang; Qiang Pan; Ying Han; Xiaoming Wang; Qintong Li; Jun Qin
Journal:  J Clin Invest       Date:  2017-08-21       Impact factor: 14.808

Review 3.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

4.  Chromatin remodeling ATPase BRG1 and PTEN are synthetic lethal in prostate cancer.

Authors:  Yufeng Ding; Ni Li; Baijun Dong; Wangxin Guo; Hui Wei; Qilong Chen; Huairui Yuan; Ying Han; Hanwen Chang; Shan Kan; Xuege Wang; Qiang Pan; Ping Wu; Chao Peng; Tong Qiu; Qintong Li; Dong Gao; Wei Xue; Jun Qin
Journal:  J Clin Invest       Date:  2019-01-14       Impact factor: 14.808

Review 5.  From genomics to functions: preclinical mouse models for understanding oncogenic pathways in prostate cancer.

Authors:  Chuan Yu; Kevin Hu; Daniel Nguyen; Zhu A Wang
Journal:  Am J Cancer Res       Date:  2019-10-01       Impact factor: 6.166

Review 6.  Genetically Engineered Mouse Models of Prostate Cancer in the Postgenomic Era.

Authors:  Juan M Arriaga; Cory Abate-Shen
Journal:  Cold Spring Harb Perspect Med       Date:  2019-02-01       Impact factor: 6.915

7.  NSD2 dimethylation at H3K36 promotes lung adenocarcinoma pathogenesis.

Authors:  Deepanwita Sengupta; Liyong Zeng; Yumei Li; Simone Hausmann; Debopam Ghosh; Gang Yuan; Thuyen N Nguyen; Ruitu Lyu; Marcello Caporicci; Ana Morales Benitez; Garry L Coles; Vladlena Kharchenko; Iwona Czaban; Dulat Azhibek; Wolfgang Fischle; Mariusz Jaremko; Ignacio I Wistuba; Julien Sage; Łukasz Jaremko; Wei Li; Pawel K Mazur; Or Gozani
Journal:  Mol Cell       Date:  2021-09-22       Impact factor: 17.970

8.  Global Regulation of the Histone Mark H3K36me2 Underlies Epithelial Plasticity and Metastatic Progression.

Authors:  Salina Yuan; Ramakrishnan Natesan; Francisco J Sanchez-Rivera; Jinyang Li; Natarajan V Bhanu; Taiji Yamazoe; Jeffrey H Lin; Allyson J Merrell; Yogev Sela; Stacy K Thomas; Yanqing Jiang; Jacqueline B Plesset; Emma M Miller; Junwei Shi; Benjamin A Garcia; Scott W Lowe; Irfan A Asangani; Ben Z Stanger
Journal:  Cancer Discov       Date:  2020-03-18       Impact factor: 39.397

Review 9.  Post-Translational Modifications That Drive Prostate Cancer Progression.

Authors:  Ivana Samaržija
Journal:  Biomolecules       Date:  2021-02-09

Review 10.  Epigenetic Editing in Prostate Cancer: Challenges and Opportunities.

Authors:  Mariana Brütt Pacheco; Vânia Camilo; Rui Henrique; Carmen Jerónimo
Journal:  Epigenetics       Date:  2021-06-15       Impact factor: 4.861

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.